Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma
Authors
Keywords
-
Journal
JOURNAL OF NEURO-ONCOLOGY
Volume 108, Issue 3, Pages 499-506
Publisher
Springer Nature
Online
2012-03-10
DOI
10.1007/s11060-012-0848-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Substrate-dependent modulation of the catalytic activity of CYP3A by erlotinib
- (2011) Pei-pei Dong et al. ACTA PHARMACOLOGICA SINICA
- Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma
- (2011) W. Wu et al. NEURO-ONCOLOGY
- A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
- (2011) J. J. Raizer et al. NEURO-ONCOLOGY
- Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors
- (2010) Faye M. Johnson et al. CANCER
- Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non–Small-Cell Lung Cancer
- (2010) Eric B. Haura et al. JOURNAL OF CLINICAL ONCOLOGY
- Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure
- (2010) C. Lu-Emerson et al. JOURNAL OF NEURO-ONCOLOGY
- Inhibition of Mer and Axl Receptor Tyrosine Kinases in Astrocytoma Cells Leads to Increased Apoptosis and Improved Chemosensitivity
- (2010) A. K. Keating et al. MOLECULAR CANCER THERAPEUTICS
- Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study
- (2010) W. K. A. Yung et al. NEURO-ONCOLOGY
- Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
- (2010) E F Dunn et al. ONCOGENE
- Dasatinib, a Multikinase Inhibitor: Therapy, Safety, and Appropriate Management of Adverse Events
- (2010) Sepideh Shayani THERAPEUTIC DRUG MONITORING
- Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
- (2009) Martin J. van den Bent et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of the Effect of Gastric Acid pH Modulators on the Bioavailability of Oral Dasatinib in Healthy Subjects
- (2009) Timothy Eley et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma
- (2009) V. Milano et al. MOLECULAR CANCER THERAPEUTICS
- The Protein Phosphatase Activity of PTEN Regulates Src Family Kinases and Controls Glioma Migration
- (2008) N. Dey et al. CANCER RESEARCH
- Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate
- (2008) M. Brave et al. CLINICAL CANCER RESEARCH
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- (2008) Roger McLendon et al. NATURE
- Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy
- (2008) Jinyan Du et al. NATURE BIOTECHNOLOGY
- Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
- (2008) Kathleen R. Lamborn et al. NEURO-ONCOLOGY
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme
- (2008) D. W. Parsons et al. SCIENCE
- Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma
- (2008) Tim F Cloughesy et al. PLOS MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started